RMD stock sentiment todayResMed Inc.

ResMed is proving that GLP-1 fears were overblown by delivering massive margin expansion and operational leverage even as the stock sees short-term profit taking.

Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for RMD. Not financial advice.

The narrative is a tug-of-war between stellar Q1/Q3 earnings beats and the persistent shadow of GLP-1 weight-loss drugs reducing the patient pool. While headlines highlight dividend strength and revenue beats, the recent -6.74% dip suggests the market is wrestling with a 'fully valued' label following a massive recovery rally.

• ·GLP-1 impact skepticism vs. actual patient growth
• ·Consistent earnings and revenue beats
• ·Supply chain recovery and market share gains from Philips' recall
• ·Dividend reliability for income-focused investors

ResMed boasts best-in-class gross margins (climbing toward 59%) and robust free cash flow. Despite high valuation multiples (Forward P/E ~25-28x), its double-digit revenue growth and aggressive debt paydown make it a quality compounder.

• ·Gross Margin expansion driven by manufacturing efficiencies
• ·Double-digit revenue growth in both Device and SaaS segments
• ·Robust Operating Cash Flow allowing for consistent buybacks and dividends
• ·Significant reduction in Net Debt/EBITDA leverage

Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.

Strong conviction — insiders and patient capital are backing this.

• ·No open-market insider trades in the last 120 days.

Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.

• ·Long-term total addressable market (TAM) erosion if GLP-1s significantly reduce sleep apnea prevalence
• ·Potential re-entry of Philips into the US sleep market after consent decree resolution
• ·High valuation sensitivity to any guidance misses

How direct competitors stack up against RMD right now.

• COLD
  PHGKoninklijke Philips N.V.

  COLDER — struggling with lingering brand damage and legal liabilities from massive respiratory recalls while ResMed eats their market share.

  See full analysis →
• NEUTRAL
  FISVFisher & Paykel Healthcare

  NEUTRAL — premium valuation similar to RMD but lacks the same aggressive software/SaaS integration scale in the US market.

  See full analysis →
• HOT
  IHRTInspire Medical Systems

  HOTTER — higher risk/reward profile with faster revenue growth as a disruptive implantable alternative to CPAP therapy.

  See full analysis →

Consensus average of 12 analysts · median 260.00

Source: StockAnalysis.com · updated 2026-10-30

• Trefis
  What Sent ResMed Stock Lower?
• Yahoo Finance
  RMD Stock Up on Q1 Earnings and Revenue Beat, Gross Margin Climbs
• 24/7 Wall St.
  75 and Stocks Are Down? Your RMD Doesn’t Have to Come From the Bottom
• ChartMill
  ResMed (NYSE:RMD) Delivers Quality Dividend Strength for Income Investors
• Yahoo Finance
  RMD Q3 deep dive: product innovation and supply chain execution drive results amid evolving landscape
• Yahoo Finance
  ResMed (RMD) Looks Fully Valued After Another Earnings Beat